Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Paying For Essentials: Fight Brewing Over Specialty Tiers In Exchange Plans

Executive Summary

Biopharmaceutical companies, patient groups and other stakeholders are pushing for federal guidelines specifically barring the use of formulary specialty tiers in private health insurance plans for individuals and small groups.

You may also be interested in...

HHS Essential Health Benefits Standard Would Allow Plans To Cover One Drug Per Category

Released Dec. 16, the HHS bulletin previews the regulatory approach the department plans to propose to define covered services under the EHB standard, which must be followed by plans participating in state-based insurance exchanges that will start operating in 2014 under the Affordable Care Act.

HHS Essential Health Benefits Should Establish "Protected" Drug Classes, As In Part D, BIO Says

BIO advises HHS officials in an Oct. 25 "listening session" that the essential health benefits regulations for private insurance plans should incorporate a number of Medicare Part D formulary policies - except the one that allows use of specialty tiers.

State Bills Setting Specialty Tier Limits Await Health Reform Developments

Legislation is pending in a number of states that would ban or set limits around the use of formulary specialty tiers in private insurance. However, most of the bills appear to be on hold pending implementation over the next six to eight months of new insurance requirements under the health reform law.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts